Stelrad Group (SRAD) Competitors

Stelrad Group (LON:SRAD) and Dr. Martens (LON:DOCS) are both small-cap computer software companies, but which is the superior stock? We will contrast the two businesses based on the strength of their risk, earnings, media sentiment, dividends, analyst recommendations, institutional ownership, valuation and profitability.

Does the media favor SRAD or DOCS?

In the previous week, Dr. Martens had 9 more articles in the media than Stelrad Group. MarketBeat recorded 9 mentions for Dr. Martens and 0 mentions for Stelrad Group. Dr. Martens' average media sentiment score of 0.67 beat Stelrad Group's score of 0.00 indicating that Dr. Martens is being referred to more favorably in the news media.

Company	Overall Sentiment
Stelrad Group	Neutral
Dr. Martens	Positive

Which has stronger valuation & earnings, SRAD or DOCS?

Dr. Martens has higher revenue and earnings than Stelrad Group. Dr. Martens is trading at a lower price-to-earnings ratio than Stelrad Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Stelrad Group	£306.97M	0.73	£16.13M	£11.64	14.52
Dr. Martens	£874.20M	0.87	£68.97M	£7.05	11.06

Which has more volatility & risk, SRAD or DOCS?

Stelrad Group has a beta of 0.25, meaning that its stock price is 75% less volatile than the S&P 500. Comparatively, Dr. Martens has a beta of 0.11, meaning that its stock price is 89% less volatile than the S&P 500.

Is SRAD or DOCS more profitable?

Dr. Martens has a net margin of 7.89% compared to Stelrad Group's net margin of 5.25%. Stelrad Group's return on equity of 28.08% beat Dr. Martens' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Stelrad Group	5.25%	28.08%	7.46%
Dr. Martens	7.89%	18.91%	8.12%

Do analysts recommend SRAD or DOCS?

Dr. Martens has a consensus price target of GBX 6,000, indicating a potential upside of 7,587.38%. Given Dr. Martens' stronger consensus rating and higher possible upside, analysts clearly believe Dr. Martens is more favorable than Stelrad Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Stelrad Group	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Dr. Martens	0 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00

Is SRAD or DOCS a better dividend stock?

Stelrad Group pays an annual dividend of GBX 8 per share and has a dividend yield of 4.7%. Dr. Martens pays an annual dividend of GBX 3 per share and has a dividend yield of 3.8%. Stelrad Group pays out 68.7% of its earnings in the form of a dividend. Dr. Martens pays out 42.5% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years.

Do insiders and institutionals have more ownership in SRAD or DOCS?

35.5% of Stelrad Group shares are owned by institutional investors. Comparatively, 69.5% of Dr. Martens shares are owned by institutional investors. 64.4% of Stelrad Group shares are owned by insiders. Comparatively, 4.4% of Dr. Martens shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Summary

Dr. Martens beats Stelrad Group on 11 of the 17 factors compared between the two stocks.